Last reviewed · How we verify
B244
At a glance
| Generic name | B244 |
|---|---|
| Sponsor | AOBiome LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis (PHASE2)
- A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis (PHASE1)
- Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis (PHASE1, PHASE2)
- Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis (PHASE2)
- Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine (PHASE2)
- A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea (PHASE2)
- Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris (PHASE2, PHASE3)
- A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- B244 CI brief — competitive landscape report
- B244 updates RSS · CI watch RSS
- AOBiome LLC portfolio CI